ABSTRACT
INTRODUCTION
Photodynamic therapy (PDT) is a clinical treatment resulting from the interaction of a photosensitizer, molecular oxygen and light of a specific wavelength. When all three components are combined simultaneously in sufficient amounts they result in the production of singlet oxygen and other free radicals causing diseased cells to undergo cell death through necrosis or apoptosis (1) . An increased or excessive amount of photosensitizer would be clinically useful and so research is taking place to try to increase photosensitizer accumulation during PDT with a view to ultimately enhancing clinical efficacy.
The prodrugs aminolevulinic acid (ALA), methyl aminolevulinate (MAL) and hexyl aminolevulinate (HAL) are porphyrin-inducing precursors of the endogenous photosensitizer protoporphyrin IX (PpIX) produced via the heme biosynthesis pathway in nucleated cells in humans. Usually in cells, following PpIX production the next stage in the pathway is the insertion of ferrous iron (Fe 2+ ) under the action of the ferrochelatase enzyme (2) , to convert PpIX into heme, with the presence of free heme acting as a negative feedback mechanism limiting the production of any further ALA (3) . However, the exogenous introduction of large amounts of ALA/MAL/HAL bypasses this negative feedback loop and there is a resultant accumulation of heme and heme precursors in the cell. Notably, the conversion of PpIX to heme by ferrochelatase is relatively slow which causes PpIX to temporarily accumulate within cells (4) .
In addition, in diseased cells some enzymes within the heme biosynthesis pathway are over or under expressed favoring the continual production of PpIX (5-7).
The first results from a clinical trial utilizing ALA-induced PpIX photodynamic therapy were reported just over 20 years ago (8) and since then PpIX-induced PDT for a variety of cancers has been investigated. Topically it can be used for the treatment of a number of 4 dermatological indications including the most common form of skin cancer, basal cell carcinoma (BCC). Although PpIX-induced PDT produces good clinical outcomes and excellent cosmesis for the thinner, superficial BCCs (sBCC), efficacy for the treatment of thicker nodular BCCs (nBCC) remains lower than conventional surgical excision (9) . For patients presenting with nBCC lesions that are large, multiple and/or on cosmetically sensitive sites (10) , surgical excision can be a disfiguring and distressing experience. Therefore, enhancement of PpIXinduced PDT for these thicker lesions would be beneficial.
Another promising application of PpIX accumulation within cancer cells is within human brain tumor cells. Human glioblastomas are aggressive primary brain tumors which remain the most common form of this malignancy (11) and problematic to treat given their infiltrative and mobile characteristics (12) . Conventional treatments for brain tumors include surgery, radiotherapy and chemotherapy. Although these conventional therapies are potentially curative, the 5 year survival rates remain below 5%, with approximately 80% of reoccurrences occurring within 2 cm of the surgically resected margin (13 (2) . DFO has greater specificity for iron than EDTA and research by our group has shown 1,2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94) to be significantly superior to DFO in the enhancement of PpIX accumulation using ALA and MAL in fetal lung fibroblasts and squamous carcinoma cells (19) .
Dexrazoxane (ICRF-187) is a clinically approved anthracycline-induced cardioprotective agent which has been used for more than 20 years (22) . Dexrazoxane's proposed mechanism of action is that it readily penetrates cell membranes, is intracellularly converted into two one-ring open intermediates followed by the production of ADR-925, which can either remove iron from the iron-anthracycline complex or bind to free iron (22) . It has been reported that all three hydrolysis products are good iron-chelating agents (23) and dexrazoxane itself is therefore known as an iron chelating prodrug.
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These findings suggest that dexrazoxane may be used clinically as a successful iron chelating prodrug to enhance PpIX accumulation and to our knowledge has not previously been investigated for this purpose. This study therefore compares the effects of the iron chelating agents CP94 and dexrazoxane, on the accumulation of PpIX within human squamous epithelial cells and human glioma cells in vitro with ALA, MAL and HAL as the porphyrin precursors.
MATERIALS AND METHODS

Chemicals and cells
All reagents and chemicals were purchased from Sigma-Aldrich Chemical Company (Poole, Under dark room conditions PpIX fluorescence quantification was conducted using a multi-well plate reader (Synergy HT, Bio-Tek, UK). Measurements were taken from the bottom of the wells with a 400 ± 30 nm excitation filter and a 645 ± 40 nm emission filter in place.
Readings were taken every hour for a total of 6 hours and under dark room conditions to reduce photobleaching of PpIX. After/between each reading, plates were kept in the dark at 5% CO2 and 37ºC.
Data analysis and statistics
The PpIX fluorescence measurements from the control cells not incubated with any test compound were used to remove natural cellular PpIX autofluorescence from all the other measurements made from the same plate. Following the determination of the presence of parametric data sets statistical significance between individual groups was determined using the Student's t-test and ANOVA was employed when considering differences between data sets.
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RESULTS
Dark toxicity of CP94 and dexrazoxane
The dark toxicity of the two iron chelating agents, CP94 and dexrazoxane, incubated alone with squamous carcinoma (A431) and glioma (U-87 MG) cells was investigated (Fig 1) . It was observed that both iron chelating agents produced similar results in each cell type with the Student's t-test revealing that at the concentrations tested no statistically significant toxicity was observed with either iron chelating agent, when compared to the same cell type incubated with modified EMEM alone (control group) (Fig 1) .
The effect of CP94 and dexrazoxane on PpIX accumulation in squamous carcinoma (A431) cells
In the human epithelial carcinoma cells (A431) incubated with the prodrugs ALA/MAL/HAL with and without the iron chelators CP94 and dexrazoxane, PpIX fluorescence levels increased hourly and using an ANOVA with a post-test a significant linear trend was found (p<0. after the first hour between HAL + CP94 and HAL + 50 µM dexrazoxane (Fig 2c) . In addition, dexrazoxane PpIX levels continued to increase (Fig 2c) . Furthermore, the PpIX levels observed with 10 µM HAL were not as great as those produced by 250 µM ALA or 1000 µM MAL.
Although the control results and ALA/MAL/HAL + CP94 results were comparable with our previous findings (24) .
The enhanced levels of PpIX fluorescence detected could be represented as reduced incubation times (Fig 2d) . In the cells incubated with MAL +/-CP94 or dexrazoxane (Fig 3b) , the levels of PpIX, although visually consistently greater when combined with CP94 were only significantly different to the MAL only controls and those treated with 50 µM or 150 µM dexrazoxane at 0 and 1 hr. In the cells incubated with HAL alone and with HAL + 50 µM dexrazoxane levels of PpIX fluorescence were observed to decrease following 5 hours, whereas following 5 hours incubation with HAL + CP94 or HAL + 150 µM dexrazoxane PpIX levels continue to increase (Fig 3c) . In addition, following 4 hours plus incubation, levels of PpIX fluorescence were significantly greater when cells were incubated with HAL + 150 µM dexrazoxane compared to incubation with HAL + CP94 (p<0.05).
The enhanced levels of PpIX fluorescence detected could again be represented as reduced incubation times (Fig 3d) . shown CP94 to be significantly superior to the well-known iron chelator DFO (21) at increasing levels of PpIX (19) . In addition, CP94 combined with ALA has been tested in vivo, with the PpIX fluorescence produced in rat colonic mucosa double that of ALA alone (25) . An ongoing 14 clinical investigation using increasing concentrations of CP94 combined with ALA or MAL to carry out PDT on nBCCs which after 6 weeks are surgically excised, is currently being undertaken. Clinical assessment prior to excisions has so far demonstrated that using ALA + 40% CP94 produced a significantly greater clearance rate in nBCCs than with ALA-PDT alone (26) . The clinical use of CP94 however remains experimental and non-licensed at the current time. However, dexrazoxane is already approved and used clinically, exerting its iron chelating properties successfully as a protective agent for anthracycline-induced cardiotoxicity. Therefore, comparing the iron chelating efficacies of CP94 and dexrazoxane with their ability to increase PpIX accumulation is useful, and to our knowledge this is the first study to investigate the combined interaction of any PpIX precursor with dexrazoxane.
In the human squamous epithelial carcinoma cells (A431) both CP94 and dexrazoxane treatment groups increased PpIX fluorescence when combined with the three prodrugs ALA/MAL/HAL, compared to each prodrug alone and markedly, CP94 produced significantly greater levels of PpIX accumulation when compared to dexrazoxane for each of the prodrugs tested. In addition, in A431 cells treated with CP94 and dexrazoxane, at both concentrations tested, the same amount of PpIX fluorescence normally produced during 6 hour incubation with ALA/MAL/HAL was produced within shorter time periods. Notably, this level of fluorescence was reached 3 times quicker when ALA and MAL were combined with CP94 and 6 times quicker when HAL was combined with CP94. Currently, dermatology PDT clinic drug-lightinterval times are 4-6 hours for ALA and 3 hours for MAL (27) . This time is important to allow for optimum levels of PpIX to accumulate and to produce an optimum ratio of photosensitizer accumulation between tumor and non tumor tissues (19) . The results from this study suggest dermatology PDT clinics may benefit most from inclusion of CP94 in their treatment regimes to 15 firstly reduce incubation times resulting in a greater number of treatments being feasible in a day and thus reduced waiting times for patients and secondly to increase efficacy in applications requiring enhancement. However, use of the more clinically acceptable dexrazoxane may also produce some clinical benefits, and warrants further investigation.
In A431 cells it has been demonstrated here that CP94 is a greater enhancer of PpIX accumulation than both concentrations of dexrazoxane investigated, for each of the PpIX precursors tested. Notably, dexrazoxane was employed at two concentrations; 50 µM and 150 µM, whereas CP94 was only employed at 150 µM. This was done to take into account the different iron binding equivalences of the two iron chelating agents. Dexrazoxane is hexadentate meaning a single Fe molecule is coordinated by one chelator molecule in a 1:1 ratio. CP94 is bidentate meaning it binds iron in the ratio of 3:1. As a result the concentrations employed were chosen to produce solutions of equal iron binding equivalence (150 µM CP94 vs 50 µM dexrazoxane) and fairly compared equimolar concentrations of each iron chelating agent (150 µM) but in each case CP94 out performed dexrazoxane.
The end hydrolysis product of dexrazoxane, ADR-925 is a cyclic derivative of EDTA which has been investigated previously as an enhancer of PpIX-induced PDT (20). The polar nature of ADR-925, like that of EDTA prevents it from being able to cross cell membranes but this obstacle is overcome when dexrazoxane is employed instead of EDTA as its likely mode of transport is passive diffusion across cell membranes, similar to that shown for ICRF-159 (razoxane) (28) . As CP94 and dexrazoxane can both readily enter cells one could postulate the decreased efficacy of dexrazoxane to increase PpIX accumulation compared to CP94, might be explained by dexrazoxane's conversion to its hydrolysis products. Physiological conditions studies (29, 30) have demonstrated that dexrazoxane is hydrolyzed to its one-ring open intermediates with a T1/2 of 9.3 hr at 37ºC and pH 7.4, whereas the final hydrolysis product ADR-925 was produced with a T1/2 of 23 hr. In the present study incubation times of up to 6 hours only were employed but PpIX accumulation was still observed to occur at a greater level when each PpIX precursor was combined with dexrazoxane than incubation with each PpIX precursor alone. This could be explained by the observation that dexrazoxane can be enzymatically hydrolyzed, more rapidly, by dihydropyrimidine amidohydrolase (DHPase) to its
one-ring open intermediates (31, 32) , which like ADR-925 are also able to chelate iron. In addition, nonenzymatic metal-ion-promoted hydrolysis of dexrazoxane has also been reported (23, 33) 
